Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Agenus Inc. provided a stakeholder update, emphasizing the urgent need for new colorectal cancer treatments, particularly for 'cold tumors,' which their BOT/BAL immunotherapy aims to address. Compelling Phase I data in late-stage MSS CRC showed a 42% two-year survival rate and 21-month median overall survival, significantly surpassing current standards. Two key trials, the first-line BB-OPCO and the late-line Phase III BATTMAN (submitted to Health Canada for international registration), are progressing, despite past regulatory delays that have now seen the FDA agree to a two-arm trial design. Furthermore, Agenus's MiNK Therapeutics subsidiary is advancing iNKT cell therapies with broad applications beyond oncology, including infectious diseases, drawing government interest and adding significant value. Financially, the company is finalizing the sale of its Emeryville manufacturing facility to Zydus (pending Treasury clearance) and pursuing additional financing, aiming to retain core BOT/BAL rights and accelerate patient access.

Analysis

Agenus Inc. (AGEN) is advancing its botensilimab/balstilimab (BOT/BAL) immunotherapy combination, targeting the significant unmet need in microsatellite stable (MSS) or "cold tumor" colorectal cancer (CRC), which constitutes 85-95% of cases. The company presented compelling Phase I data in heavily pre-treated, late-stage MSS CRC patients, demonstrating a 42% two-year survival rate and a median overall survival of 21 months, substantially outperforming the 6-11 month survival seen with current standards of care. The path to registration is now clearer following a key regulatory concession where the FDA agreed to a two-arm Phase III study design, resolving a previous delay. This pivotal 'BATTMAN' trial is being initiated internationally with the Canadian Cancer Trials Group and partners, aiming to enroll 834 patients, with high investigator enthusiasm suggesting rapid recruitment. Beyond this late-line strategy, Agenus has significant upside potential in earlier treatment settings; the investigator-initiated BB-OPCO trial is evaluating BOT/BAL as a first-line, chemotherapy-free option, while neoadjuvant studies are showing remarkable pathologic response rates of over 40% in just weeks. Financially, the company is addressing its funding needs through the imminent closure of its Emeryville facility sale to Zydus, having already secured HSR clearance, and is in advanced discussions for another significant financing deal that would preserve rights to BOT/BAL in key markets. Further value exists in Agenus's ~48% ownership of MiNK Therapeutics (INKT), which is developing a unique 'off-the-shelf' iNKT cell therapy platform with applications in both oncology and government-funded biodefense against infectious diseases.

Key Decisions for Investors

• Investors should monitor for near-term financial catalysts, specifically the final closure of the Zydus manufacturing facility sale and the announcement of a new partnership, as these are critical to funding the pivotal BATTMAN trial and de-risking the balance sheet.
• The primary valuation driver is the execution of the Phase III BATTMAN trial; tracking enrollment progress against the projected 60 patients per month and eventual data readouts will be key to assessing the path to commercialization in the large late-line MSS CRC market.
• Consider the significant long-term upside optionality from earlier-line settings, as positive data from the first-line BB-OPCO and various neoadjuvant trials could dramatically expand the addressable market for BOT/BAL beyond its initial indication.
• Acknowledge the embedded value of Agenus's ~48% stake in MiNK Therapeutics (INKT), as its distinct iNKT cell therapy platform represents a non-correlated asset with potential in high-interest areas like biodefense, offering a source of value independent of the BOT/BAL program.